Brinzolamide-timolol suspension is well-tolerated in glaucoma patients

Article

The administration of brinzolamide-timolol suspension has a minimal effect on quality of life and is generally favoured when compared with other drops, according to a study published in Clinical Ophthalmology.

The administration of brinzolamide-timolol suspension has a minimal effect on quality of life and is generally favoured when compared with other drops, according to a study published in Clinical Ophthalmology.

Dr M. Doherty et al., Sunderland Eye Infirmary, Sunderland, Tyne and Wear, distributed a questionnaire to 76 patients listed under the Sunderland Eye Infirmary Glaucoma Service who were administered the brinzolamide-timolol suspension. The questions involved effects on daily life, visiual blurring, stinging, irritation and acceptability to the topical ocular antihypertensive preparation. Answers were ranked using a numerical scale from 0 to 10.

All patients participated and included 58 females and 18 males all aged between 68–95 years. The treatment ranged from 3 to 7 months.It was found that the patient's quality of life was hardly affected with a rating between 0 and 2. Stinging and irritation were also low scoring in the responses but visual blurring was rated a little higher, at 3 on average. Addiotionally, the majority of respondents preferred brinzolamide-timolol suspension over other topical medications.

The findings demonstrate that brinzolamide-timolol suspension is an acceptable medication with few side effects.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.